Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rupert Bartsch

Showing results (21-30 of 228) with videos related to

Pageof 23
Sort By:
ESMO Open|November 16, 2016
Recent developments and translational aspects in targeted therapy for metastatic breast cancerMaximilian Marhold, Rupert Bartsch, Christoph Zielinski
Journal of Geriatric Oncology|June 8, 2023
Dexamethasone-sparing regimens with NEPA (netupitant/palonosetron) for the prevention of chemotherapy-induced nausea and vomiting in older patients (>65 years) fit for cisplatin: A sub-analysis from a phase 3 studyLuigi Celio, Rupert Bartsch, Matti Aapro
Breast Care (Basel, Switzerland)|January 27, 2022
Position Paper on the Value of Extended Adjuvant Therapy with Neratinib for Early HER2+/HR+ Breast CancerMarija Balic, Gabriel Rinnerthaler, Rupert Bartsch
Memo|September 18, 2018
Current concepts and future directions in neoadjuvant chemotherapy of breast cancerRupert Bartsch, Elisabeth Bergen, Arik Galid
Memo|April 3, 2018
ESMO 2017-my personal highlightsBarbara Kiesewetter, Mircea Dediu, Rupert Bartsch
Expert Opinion on Pharmacotherapy|December 19, 2015
Palbociclib for the treatment of postmenopausal breast cancer - an updateGuenther G Steger, Michael Gnant, Rupert Bartsch
Journal of Neuro-Oncology|September 26, 2013
Breast cancer brain metastases responding to primary systemic therapy with T-DM1Rupert Bartsch, Anna S Berghoff, Matthias Preusser
The Lancet. Oncology|May 16, 2016
Pathological complete remission and long-term outcome-what do we know in 2016?Michael Gnant, Guenther G Steger, Rupert Bartsch
The Lancet. Oncology|May 6, 2014
HER2-positive breast cancer: a new piece of the puzzleMichael Gnant, Rupert Bartsch, Guenther G Steger
CNS Drugs|December 15, 2012
Optimal management of brain metastases from breast cancer. Issues and considerationsRupert Bartsch, Anna S Berghoff, Matthias Preusser
Pageof 23

Showing results (21-30 of 228) with videos related to

Sort By:
Pageof 23
ESMO Open|November 16, 2016
Recent developments and translational aspects in targeted therapy for metastatic breast cancerMaximilian Marhold, Rupert Bartsch, Christoph Zielinski
Journal of Geriatric Oncology|June 8, 2023
Dexamethasone-sparing regimens with NEPA (netupitant/palonosetron) for the prevention of chemotherapy-induced nausea and vomiting in older patients (>65 years) fit for cisplatin: A sub-analysis from a phase 3 studyLuigi Celio, Rupert Bartsch, Matti Aapro
Breast Care (Basel, Switzerland)|January 27, 2022
Position Paper on the Value of Extended Adjuvant Therapy with Neratinib for Early HER2+/HR+ Breast CancerMarija Balic, Gabriel Rinnerthaler, Rupert Bartsch
Memo|September 18, 2018
Current concepts and future directions in neoadjuvant chemotherapy of breast cancerRupert Bartsch, Elisabeth Bergen, Arik Galid
Memo|April 3, 2018
ESMO 2017-my personal highlightsBarbara Kiesewetter, Mircea Dediu, Rupert Bartsch
Expert Opinion on Pharmacotherapy|December 19, 2015
Palbociclib for the treatment of postmenopausal breast cancer - an updateGuenther G Steger, Michael Gnant, Rupert Bartsch
Journal of Neuro-Oncology|September 26, 2013
Breast cancer brain metastases responding to primary systemic therapy with T-DM1Rupert Bartsch, Anna S Berghoff, Matthias Preusser
The Lancet. Oncology|May 16, 2016
Pathological complete remission and long-term outcome-what do we know in 2016?Michael Gnant, Guenther G Steger, Rupert Bartsch
The Lancet. Oncology|May 6, 2014
HER2-positive breast cancer: a new piece of the puzzleMichael Gnant, Rupert Bartsch, Guenther G Steger
CNS Drugs|December 15, 2012
Optimal management of brain metastases from breast cancer. Issues and considerationsRupert Bartsch, Anna S Berghoff, Matthias Preusser
Pageof 23